Xponance Inc. Buys 844 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Xponance Inc. raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO) by 9.1% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 10,089 shares of the company’s stock after acquiring an additional 844 shares during the period. Xponance Inc.’s holdings in BridgeBio Pharma were worth $277,000 as of its most recent SEC filing.

Several other hedge funds have also bought and sold shares of the stock. Janus Henderson Group PLC increased its holdings in shares of BridgeBio Pharma by 11.7% in the third quarter. Janus Henderson Group PLC now owns 4,818,012 shares of the company’s stock worth $122,658,000 after purchasing an additional 505,481 shares during the last quarter. Erste Asset Management GmbH purchased a new position in BridgeBio Pharma during the 3rd quarter valued at approximately $3,497,000. Exome Asset Management LLC increased its stake in BridgeBio Pharma by 167.4% in the 3rd quarter. Exome Asset Management LLC now owns 211,000 shares of the company’s stock worth $5,372,000 after acquiring an additional 132,093 shares during the last quarter. Barclays PLC raised its holdings in shares of BridgeBio Pharma by 31.9% during the 3rd quarter. Barclays PLC now owns 545,008 shares of the company’s stock worth $13,876,000 after acquiring an additional 131,743 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. boosted its position in shares of BridgeBio Pharma by 3.5% during the 3rd quarter. Frazier Life Sciences Management L.P. now owns 3,760,457 shares of the company’s stock valued at $95,741,000 after acquiring an additional 127,853 shares during the last quarter. Hedge funds and other institutional investors own 99.85% of the company’s stock.

Wall Street Analysts Forecast Growth

BBIO has been the topic of a number of recent research reports. Evercore ISI upped their price target on shares of BridgeBio Pharma from $45.00 to $50.00 and gave the company an “outperform” rating in a research note on Monday, December 23rd. HC Wainwright reissued a “buy” rating and set a $49.00 price objective on shares of BridgeBio Pharma in a research note on Thursday, February 13th. JPMorgan Chase & Co. raised their price target on BridgeBio Pharma from $44.00 to $50.00 and gave the stock an “overweight” rating in a research report on Monday. Scotiabank boosted their price objective on shares of BridgeBio Pharma from $49.00 to $52.00 and gave the company a “sector outperform” rating in a research report on Friday, February 21st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $95.00 price target on shares of BridgeBio Pharma in a research note on Friday, February 21st. One research analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $52.90.

BridgeBio Pharma Price Performance

Shares of BBIO stock opened at $36.40 on Friday. The company has a market capitalization of $6.92 billion, a P/E ratio of -12.77 and a beta of 1.07. The company’s 50-day simple moving average is $34.24 and its two-hundred day simple moving average is $29.26. BridgeBio Pharma, Inc. has a one year low of $21.62 and a one year high of $39.47.

BridgeBio Pharma (NASDAQ:BBIO) last announced its quarterly earnings data on Thursday, February 20th. The company reported ($1.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.09) by ($0.22). The company had revenue of $5.88 million during the quarter, compared to the consensus estimate of $4.04 million. On average, research analysts expect that BridgeBio Pharma, Inc. will post -3.67 EPS for the current fiscal year.

Insider Transactions at BridgeBio Pharma

In other news, CEO Neil Kumar sold 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $36.87, for a total value of $2,765,250.00. Following the completion of the sale, the chief executive officer now owns 4,948,447 shares of the company’s stock, valued at approximately $182,449,240.89. This represents a 1.49 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Global Investors Lp Viking sold 3,065,616 shares of BridgeBio Pharma stock in a transaction that occurred on Friday, January 31st. The shares were sold at an average price of $34.90, for a total transaction of $106,989,998.40. Following the transaction, the insider now directly owns 22,055,375 shares in the company, valued at approximately $769,732,587.50. The trade was a 12.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 9,654,739 shares of company stock valued at $325,937,151. 24.66% of the stock is currently owned by corporate insiders.

About BridgeBio Pharma

BridgeBio Pharma, Inc, a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.